The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research
Markus Borner(University of Bern), A. Roth(University Hospital of Zurich), Piercarlo Saletti(Institute of Oncology Research), Richard Herrmann(Heidelberg University), Răzvan Popescu(Hirslanden Klinik Aarau), D. Dietrich(Swiss Group For Clinical Cancer Research), Daniel Rauch(Washington University in St. Louis), J. Bernhard(International Breast Cancer Study Group), Martin Wernli(Kantonsspital Aarau)
Cited by 0
Related Papers
Proteome Organization in a Genome-Reduced Bacterium
|Science|2009|472
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
|JNCI Journal of the National Cancer Institute|2012|279